For: | Cernea S, Onișor D, Roiban AL, Benedek T, Rat N. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes. World J Cardiol 2024; 16(10): 580-594 [PMID: 39492975 DOI: 10.4330/wjc.v16.i10.580] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v16/i10/580.htm |
Number | Citing Articles |
1 |
Wei Wang, Charlie Cooper. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression. World Journal of Cardiology 2025; 17(1): 102467 doi: 10.4330/wjc.v17.i1.102467
|
2 |
Jiayang Lin, Ruxin Chen, Junlin Huang, Yating Liu, Chensihan Huang, Yan Huang, Bingyan Xu, Yunqian Li, Xinyu He, Hongzhen Lv, Xueyun Wei, Peizhen Zhang, Dan Guo, Jinhua Zhang, Huijie Zhang. MASLD-related fibrosis, but not MASLD, is associated with left ventricular concentric hypertrophy in patients with type 2 diabetes. Journal of Endocrinological Investigation 2025; doi: 10.1007/s40618-025-02682-6
|
3 |
Elena-Daniela Grigorescu, Bogdan-Mircea Mihai, Georgiana-Diana Cazac-Panaite, Adina-Bianca Foșălău, Alina Onofriescu, Mariana Floria, Cristina Gena Dascălu, Alexandr Ceasovschih, Laurențiu Șorodoc, Cristina-Mihaela Lăcătușu. Age-Related Characteristics of Diastolic Dysfunction in Type 2 Diabetes Patients. Journal of Clinical Medicine 2025; 14(16): 5772 doi: 10.3390/jcm14165772
|
4 |
Danusia Onișor, Andrada Larisa Roiban, Simona Cernea. Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Patients—The Relationship with Platelets Indicators. Medicina 2024; 60(12): 2091 doi: 10.3390/medicina60122091
|